巴曲酶对急性脑梗死患者血清高敏C反应蛋白的动态影响

Effect of batroxobin on high sensitivity C-reactive protein in patients with acute cerebral infarction

目的探讨巴曲酶对急性脑梗死(ACI)患者血清高敏C反应蛋白(hsCRP)含量变化的影响,了解其减轻炎症的意义。方法选择68例急性脑梗死患者随机分为两组:治疗组34例,入院后立即给予巴曲酶10BU溶入250ml生理盐水,静脉滴注,1～1.5小时滴完;第3天、第5天各给予巴曲酶5BU,其他用药同对照组;对照组34例,每日静脉滴注三七总苷(商品名:血塞通)注射液0.6g/d;应用散射免疫比浊法检测治疗前、治疗后7天、14天的血清高敏C反应蛋白水平变化,并对神经功能缺损进行标准评分。结果两组hsCRP水平在梗死后第7天最高,随后逐渐降低。治疗组在治疗前、第14天血清hsCRP水平和治疗前、第7天的神经功能缺损总分与对照组患者比较差异无统计学意义(P>0.05),治疗后第7天治疗组hsCRP水平[(8.73±3.15)mg/L]低于对照组[(10.78±3.26)mg/L](P<0.05);但第14天治疗组神经功能缺损总分(11.38±5.08)与对照组(15.91±5.85)比较差异有统计学意义(P<0.01)。结论巴曲酶能明显降低ACI患者血清hsCRP水平,有利于减轻炎症反应,改善脑梗死部位缺血缺氧和缺损神经功能。

Objective To investigate the relationship between batroxobin and serum high sensitivity C-reactive protein(hsCRP)in the patients with acute cerebral infarction(ACI). Methods Sixty-eight patients with cerebral infarction were divided two groups randomly. The treatment group(n=34), the patients were given the dosage 10 BU of batroxobin at first time,commonly given every other day for three times day with a dosage of 5 BU.It should be diluted with 250 ml of 0.9% sodium chloride solution before intravenous influsion for 1～ 1.5 hours. Conventional treatment for patients of both groups was the same except for bartroxobin. Patients of the control group were given 0.6 g/d of Xuesetong by IV instillation q.d.The course of treatment in the two groups lasted 14 days. The neurologic impairment scores were noted down and concentrations of soluble hsCRP before the treatment and on day 7 and day 14 of the treatment. The level of serum hsCRP was measured by scatter immune turbidity method. Results hsCRP reached the highest level on 7 day and then decreased slowly.The decline in serum level of hsCRP on day 7 of the treatment was more striking in patients of the the treatment group than in the control group(P< 0.05).The decline of the neurologic impairment scores on day 14 of the treatment was that of more striking in the patients of the treatment group than that of in the control group (P< 0.01). Conclusion Batroxobin can decrease serum hsCRP and mediate cerebral ischemia and hypoxia,It means that batroxobin can play an important role in protecting brain cells and blood vessel endothelial cells,and decrease the inflammatory reaction.